Table 2.

Clinical reports of the therapeutic efficacy of tigecycline for Clostridium difficile infection (CDI).

Publication Year	Case No.	Severity of CDI 1	Duration of Tigecycline, Therapy, Days	Combination Antibiotics	Outcomes	Favor Tigecycline Therapy	Reference
2009	4	Severe	7–24 2	Monotherapy or with oral vancomycin	Clinical improvement	Yes	[59]
2010	1	Severe	14	Oral metronidazole	Clinical improvement	Yes	[60]
2010	1	Severe	18	Intravenous metronidazole and vancomycin enema	Lack of clinical improvement	No	[71]
2012	1	Severe/recurrent	10	Oral rifaximin	Clinical improvement	Yes	[68]
2012	1	Severe/recurrent	4	Oral rifaximin and vancomycin	Clinical improvement	Yes	[67]
2014	43	Severe	No data	Intravenous metronidazole and oral vancomycin	No extra-benefit in requiring colectomy, recurrence or mortality	No	[70]
2014	7	Severe/complicated	3–21	Intravenous metronidazole and oral vancomycin	Clinical improvement in 85.7% of 7 cases	Yes	[69]

¹ Defined as a white blood cell count >15,000/μL or a rise in serum creatinine to 150% of the premorbid level; severe complicated disease defined as the presence of C. difficile sepsis, ileus, or toxic megacolon; ² One patient received tigecycline at a standard dosage for 24 days, followed by an additional two weeks of tigecycline treatment interspersed with one treatment-free week.